Upstream Bio, Inc. (UPB) Stock Forecast & Price Target

Compare

25 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

UPB Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Upstream

Bio, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

UPB Stock 12 Month Forecast

Average Price Target

$75.00

▲(571.44%Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Upstream Bio, Inc. in the last 3 months. The average price target is $75.00 with a high forecast of $75.00 and a low forecast of $75.00. The average price target represents a 571.44% change from the last price of $11.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","41":"$41","76":"$76","23.5":"$23.5","58.5":"$58.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,23.5,41,58.5,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.66,15.60923076923077,20.55846153846154,25.50769230769231,30.45692307692308,35.40615384615385,40.35538461538462,45.30461538461539,50.253846153846155,55.20307692307692,60.1523076923077,65.10153846153847,70.05076923076923,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.66,15.60923076923077,20.55846153846154,25.50769230769231,30.45692307692308,35.40615384615385,40.35538461538462,45.30461538461539,50.253846153846155,55.20307692307692,60.1523076923077,65.10153846153847,70.05076923076923,{"y":75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.66,15.60923076923077,20.55846153846154,25.50769230769231,30.45692307692308,35.40615384615385,40.35538461538462,45.30461538461539,50.253846153846155,55.20307692307692,60.1523076923077,65.10153846153847,70.05076923076923,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.38,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$75.00

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$11.5

Hold

2.95%

Upside

Reiterated

06/03/25

Upstream Bio, Inc. has a moderate stock score driven by strong technical analysis indicators suggesting positive momentum. However, the financial performance poses significant risks due to operational losses and negative cash flow. Valuation remains uncertain due to the lack of earnings and dividends, typical of a growth-phase biotechnology company.

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/16/25

Upstream Bio, Inc.'s Verekitug: A Promising Contender in the TSLPR Antibody Space

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/11/25

J.P. Morgan Keeps Their Buy Rating on Upstream Bio, Inc. (UPB)

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/06/25

Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position

Yasmeen RahimiPiper Sandler

Piper Sandler

$75

Buy

571.44%

Upside

Reiterated

03/04/25

Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$11.5

Hold

2.95%

Upside

Reiterated

06/03/25

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/16/25

Upstream Bio, Inc.'s Verekitug: A Promising Contender in the TSLPR Antibody Space

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/11/25

J.P. Morgan Keeps Their Buy Rating on Upstream Bio, Inc. (UPB)

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/06/25

Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position

Yasmeen RahimiPiper Sandler

Piper Sandler

$75

Buy

571.44%

Upside

Reiterated

03/04/25

Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Upstream Bio, Inc.

1 Month

xxx

Success Rate

1/4 ratings generated profit

Average Return

-1.75%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of -1.75% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

-1.10%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of -1.10% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

3/4 ratings generated profit

Average Return

+1.00%

reiterated a buy rating last month

Copying Yaron Werber's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +1.00% per trade.

2 Years

xxx

Success Rate

3/4 ratings generated profit

Average Return

+1.00%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +1.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UPB Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, UPB has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. UPB average Analyst price target in the past 3 months is 75.00.

Each month's total comprises the sum of three months' worth of ratings.

UPB Financial Forecast

UPB Earnings Forecast

Next quarter’s earnings estimate for UPB is -$0.48 with a range of -$0.60 to -$0.35. The previous quarter’s EPS was -$0.41. UPB beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year UPB has Outperformed its overall industry.

UPB Sales Forecast

Next quarter’s sales forecast for UPB is $326.00K with a range of $0.00 to $705.00K. The previous quarter’s sales results were $613.00K. UPB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year UPB has Outperformed its overall industry.

UPB Stock Forecast FAQ

What is UPB’s average 12-month price target, according to analysts?

Based on analyst ratings, Upstream Bio, Inc.’s 12-month average price target is 75.00.

What is UPB’s upside potential, based on the analysts’ average price target?

Upstream Bio, Inc. has 571.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is UPB a Buy, Sell or Hold?

Upstream Bio, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Upstream Bio, Inc.’s price target?

The average price target for Upstream Bio, Inc. is 75.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $75.00. The average price target represents 571.44% Increase from the current price of $11.17.

What do analysts say about Upstream Bio, Inc.?

Upstream Bio, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of UPB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Upstream Bio, Inc. (UPB) Stock Forecast & Price Target

UPB Analyst Ratings

UPB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Upstream Bio, Inc.

UPB Analyst Recommendation Trends

UPB Financial Forecast

UPB Earnings Forecast

UPB Sales Forecast

UPB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts